1. Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. (1st November 2019) Authors: Mirza, MR; Dørum, A; Benigno, B; Mahner, S; Bessette, P; Bover Barcelo, IM; Berton, D; Ledermann, J; Rimel, BJ; Herrstedt, J; Lau, S; Canzler, U; Palacio Vázquez, I; Kalbacher, E; Buscema, J; Lorusso, D; Debruyne, P; Bruchim, I; Guo, W; Gupta, D Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66). (4th December 2022) Authors: Fuh, Katherine; Moore, Kathleen; Baert, Thais; Herzog, Thomas; Cibula, David; Liu, Joyce; Eberst, Laurianne; Lewin, Sharon; Secord, Angeles Alvarez; Sehouli, Jalid; Myers, Tashanna; Bamias, Aristotelis; Rimel, BJ; Colombo, Nicoletta; Franke, Amy; Shoop, Dipti; Giorgi, Ugo De; Pikiel, Joanna; Bowe... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 3 Page Start: A234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗